SYBU

Across TCGA pan-cancer cohorts, SYBU Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYBU data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SYBU Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYBU expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and OV are the cancer types where SYBU Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.479	.011	30	view →
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYBU–ACC (DFS)

Open the ACC breakdown →